Facial pigmented skin disorders amenable to Q-switched laser treatment
Conditions
Interventions
Control Group:Topical application of placebo fibre dressing
Study Group:Topical application of medical mussel adhesive protein lyophilised fibres
Sponsors
Shenzhen Second People's Hospital
Eligibility
Sex/Gender
All
Age
30 Years to 55 Years
Inclusion criteria
Inclusion criteria: 1. Aged 30-55 years, in good general health, regardless of gender; 2. Presence of facial pigmented skin disorders (e.g., seborrheic keratosis, freckles, etc.) and suitable for Q-switched laser treatment; 3. Willing to sign the informed consent form, agree to facial photography (with eyes covered during shooting), and available to cooperate with the full study schedule; 4. Willing and able to refrain from using other restorative skincare products or cosmetics, and avoid other facial interventions (such as medications, injections, or laser treatments) throughout the study period; 5. Willing and able to practice strict sun protection and avoid excessive sun exposure; 6. Agree to maintain a regular and healthy lifestyle during the trial; 7. Voluntarily participate in this clinical study and willing to accept long-term follow-up.
Exclusion criteria
Exclusion criteria: 1. Application of any topical medication to the test area within the last 2 months; 2. Participation in similar facial trials, oral drug trials, or other clinical trials within the last 2 months; 3. Undergone any medical aesthetic treatments affecting skin condition within the last 3 months, such as chemical peels, intense pulsed light (IPL), fractional laser, etc. 4. Use of antihistamines within the last week or immunosuppressants within the last month; 5. Suffering from clinically uncured inflammatory skin diseases; 6. History of keloid formation; 7. Suffering from clinically uncured inflammatory skin diseases; 8. Known allergy to the components of the test product; 9. Required to be exposed to outdoor sunlight for long periods due to work or other reasons; 10. Patients currently receiving treatment for asthma or other chronic respiratory diseases; 11. Patients with insulin-dependent diabetes; 12. Received anti-cancer chemotherapy within the last 6 months; 13. Patients with immunodeficiency or autoimmune diseases; 14. Presence of other medical issues that may affect the study results (e.g., coagulation disorders, severe hyperglycemia, hypertension, hyperlipidemia, or history of other major diseases); 15. Pregnant or lactating women; 16. Patients with mental disorders or inability to communicate; 17. Involuntary participants, those unable to complete the specified trial procedures, or other subjects deemed unsuitable by the investigator.
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Melanin value;Red spot value;patient satisfaction; | — |
Primary
| Measure | Time frame |
|---|---|
| Transepidermal Water Loss (TEWL); | — |
Countries
China
Contacts
Public ContactCuihong Lian
Shenzhen Second People's Hospital
Outcome results
None listed